Comparative Pharmacology
Head-to-head clinical analysis: SUPPRELIN LA versus ZOLADEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SUPPRELIN LA versus ZOLADEX.
SUPPRELIN LA vs ZOLADEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SUPPRELIN LA is a sterile, biodegradable, subcutaneous implant containing histrelin acetate, a synthetic nonapeptide agonist of gonadotropin-releasing hormone (GnRH). After an initial transient increase, continuous administration results in downregulation of pituitary GnRH receptors, leading to suppressed luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby reducing gonadal sex steroid production (testosterone in males, estradiol in females) to castrate levels.
Gonadotropin-releasing hormone (GnRH) agonist; initially stimulates and then suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release, leading to reduced sex steroid production.
50 mg subcutaneously once every 12 months (implant placed in inner upper arm).
3.6 mg subcutaneously every 28 days (prostate cancer, endometriosis) or 10.8 mg subcutaneously every 12 weeks (prostate cancer).
None Documented
None Documented
Terminal half-life approximately 3-4 hours; clinical suppression of luteinizing hormone and testosterone sustained for 4 weeks due to depot formulation.
Approximately 4.2 hours (subcutaneous); due to continuous release from depot formulation, effective half-life is extended to ~28 days.
Renal: <5% unchanged; hepatic metabolism; fecal elimination of metabolites.
Primarily renal (approximately 20% as unchanged drug); remainder as metabolites via biliary/fecal (approximately 80%).
Category C
Category C
GnRH Agonist
GnRH Agonist